You can't like your own messages.

bioworld

BioWorld Today

Joined Jan 05, 2011

BioWorld
$PFE at #PCNS: 36 TTR mutations studied and shown to be stabilized by Tafamidis

May. 24 at 11:02 AM

from Twitter
BioWorld
$PFE at #PCNS: “Expanded access is not a substitute for product approval. TTR-FAP patients in U.S. desperately need treatment option.”

May. 24 at 10:49 AM

from Twitter
BioWorld
$PFE at #PCNS: "In our program, we demonstrated that Tafamidis stabilizes TTR compared to placebo"

May. 24 at 10:47 AM

from Twitter
BioWorld
$PFE at #PCNS: Totality of evidence across secondary endpoints demonstrates consistency and ability to predict clinical benefit

May. 24 at 10:45 AM

from Twitter
BioWorld
$PFE at #PCNS: Tafamidis endpoints reasonably likely to predict clinical benefit in TTR-FAD

May. 24 at 10:43 AM

from Twitter
BioWorld
$PFE at #PCNS: This is the first interventional trial in TTR-FAP. There are no validated endpoints, clinical assessment tools.

May. 24 at 9:40 AM

from Twitter
BioWorld
$PFE at #PCNS: No treatment exists for TTR-FAP patients not eligible for liver transplants or who don’t respond to transplant.

May. 24 at 9:27 AM

from Twitter
BioWorld
#PCNS: $PFE plans a confirmatory efficacy trial for tafamidis. Would like to do it post-approval so patients have access to drug.

May. 24 at 9:20 AM

from Twitter
BioWorld
#PCNS meeting: $PFE is committed to developing tafamidis, either with accelerated approval or on traditional path.

May. 24 at 9:17 AM

from Twitter
BioWorld
$ONXX shares quiet after blockbuster drug Nexavar becomes the latest biotech candidate to strike out in NSCLC

May. 22 at 12:50 PM

from Twitter
BioWorld
$PPHM shares up 17% at midday on Phase IIb bavituximab data in NSCLC, but stock still trading at low end of 52-week range

May. 21 at 12:14 PM

from Twitter
BioWorld
After FDA green-lights generic Plavix, $MYL first out of the gate with 300 mg clopidogrel; awarded 180-day exclusivity

May. 17 at 5:18 PM

from Twitter
BioWorld
$CRTX diversifies its hospital portfolio with deal to acquire EKR Therapeutics for $125M in cash up front, $25M in potential milestones

May. 15 at 1:05 PM

from Twitter
BioWorld
Gutsy move into gastro market appears to pay off for $VTUS: http://t.co/I0J2b1rn

May. 15 at 9:36 AM

from Twitter
BioWorld
$VTUS hits trifecta in pivotal phase III VEN 307 trial http://t.co/tcagRmBW

May. 15 at 9:35 AM

from Twitter

Follow bioworld on StockTwits!

Follow investors and traders that match your style and get a personalized stream of news, charts, and ideas.

87 Followers

Trader Profile

Experience: Intermediate
Assets Traded: Private Companies
Approach: Growth
Holding Period: Long Term Investor

bioworld

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow bioworld on StockTwits!

Trader Profile

bioworld

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow bioworld on StockTwits!

Trader Profile

Sign in to StockTwits X

Sign in

Sign up using:

Sign in to StockTwits X

Sign up X

Join StockTwits

Sign up using:

Sign up
using:

Sign up
using: